{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:44:28Z","timestamp":1792449868406,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T00:00:00Z","timestamp":1661040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000738","name":"University of Leicester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007110","name":"Schering-Plough","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012151","name":"University Hospitals of Leicester NHS Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/M016579\/1"],"award-info":[{"award-number":["MR\/M016579\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jaip.2022.06.050","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T22:39:12Z","timestamp":1658183952000},"page":"2925-2934.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma\u2014A Randomized, Placebo-Controlled Crossover Trial (MAPLE)"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2858-1559","authenticated-orcid":false,"given":"Freda","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Busby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam G.","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris E.","family":"Brightling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane P.","family":"McDowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Diver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Shrimanker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bradding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.06.050_bib1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/thoraxjnl-2017-210531","article-title":"Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population","volume":"73","author":"Kerkhof","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2022.06.050_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2466-9-24","article-title":"Economic burden of asthma: a systematic review","volume":"9","author":"Bahadori","year":"2009","journal-title":"BMC Pulmon Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib3","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/thoraxjnl-2013-204114","article-title":"The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry","volume":"70","author":"O\u2019Neill","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2022.06.050_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thoraxjnl-2015-207630","article-title":"Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry","volume":"71","author":"Sweeney","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2022.06.050_bib5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0085-2019","article-title":"How can we minimise the use of regular oral corticosteroids in asthma?","volume":"29","author":"Bourdin","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaip.2022.06.050_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaci.2014.12.1871","article-title":"Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care","volume":"135","author":"Fajt","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.050_bib8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.06.050_bib10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib11","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib12","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2213-2600(17)30132-7","article-title":"Mepolizumab, quality of life, and severe eosinophilic asthma","volume":"5","author":"Pavord","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib14","first-page":"CD010834","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2022.06.050_bib15","first-page":"50","article-title":"Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma","volume":"PA3967","author":"Shrimanker","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2022.06.050_bib16","series-title":"National Institute for Heathcare and Care Excellence Guidelines for mepolizumab for treating severe eosinophilic asthma","year":"2021"},{"key":"10.1016\/j.jaip.2022.06.050_bib17","series-title":"Scottish Medicines Consortium Guidelines for mepolizumab (Nucala)","year":"2019"},{"key":"10.1016\/j.jaip.2022.06.050_bib18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/pst.1638","article-title":"A\u00a0recommended analysis for 2\u00a0\u00d7 2 crossover trials with baseline measurements","volume":"13","author":"Mehrotra","year":"2014","journal-title":"Pharm Stat"},{"key":"10.1016\/j.jaip.2022.06.050_bib19","first-page":"276","article-title":"On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications","volume":"109","author":"Wellek","year":"2012","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.jaip.2022.06.050_bib20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.anai.2010.04.003","article-title":"Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma","volume":"104","author":"Dente","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.06.050_bib21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1164\/rccm.200404-440OC","article-title":"\u201cRefractory\u201d eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids","volume":"170","author":"ten Brinke","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1164\/ajrccm.153.2.8564096","article-title":"Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa","volume":"153","author":"Bentley","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib23","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1164\/ajrccm.155.3.9117012","article-title":"The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation","volume":"155","author":"Djukanovi\u0107","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaci.2004.10.036","article-title":"Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-gamma-inducible protein 10 expression in asthmatic airway mucosa","volume":"115","author":"Fukakusa","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.050_bib25","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/cea.12954","article-title":"Responsiveness to oral prednisolone in severe asthma is related to the degree of eosinophilic airway inflammation","volume":"47","author":"Sousa","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.06.050_bib26","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.rmed.2013.07.014","article-title":"Phenotypic predictors of response to oral glucocorticosteroids in severe asthma","volume":"107","author":"Kupczyk","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106156","article-title":"The effects of oral corticosteroids on lung function, type-2 biomarkers and patient-reported outcomes in stable asthma: a systematic review and meta-analysis","volume":"173","author":"Busby","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.03.00027302","article-title":"Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions","volume":"21","author":"B\u00fcttner","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2022.06.050_bib29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1164\/ajrccm\/148.2.401","article-title":"Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-gamma cytokine gene expression","volume":"148","author":"Robinson","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jaip.2022.06.050_bib30","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib31","first-page":"17","article-title":"Eosinophil apoptosis and clearance in asthma","volume":"6","author":"Walsh","year":"2013","journal-title":"J\u00a0Cell Death"},{"key":"10.1016\/j.jaip.2022.06.050_bib32","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nm.3300","article-title":"Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma","volume":"19","author":"Brusselle","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/rr197","article-title":"Dissociation by steroids of eosinophilic inflammation from airway hyperresponsiveness in murine airways","volume":"4","author":"Birrell","year":"2003","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2022.06.050_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/ACI.0000000000000703","article-title":"Exploring the origin and regulatory role of mast cells in asthma","volume":"21","author":"Murphy","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.050_bib35","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1056\/NEJMoa1613125","article-title":"KIT inhibition by imatinib in patients with severe refractory asthma","volume":"376","author":"Cahill","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaci.2019.03.013","article-title":"Stratification of asthma phenotypes by airway proteomic signatures","volume":"144","author":"Schofield","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.050_bib37","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1164\/rccm.201607-1453OC","article-title":"Effects of age and disease severity on systemic corticosteroid responses in asthma","volume":"195","author":"Phipatanakul","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib38","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.4049\/jimmunol.157.6.2654","article-title":"A\u00a0novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity","volume":"157","author":"Spahn","year":"1996","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2022.06.050_bib39","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.4049\/jimmunol.1601029","article-title":"Cytokine-induced glucocorticoid resistance from eosinophil activation: protein phosphatase 5 modulation of glucocorticoid receptor phosphorylation and signaling","volume":"197","author":"Pazdrak","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2022.06.050_bib40","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01167-2017","article-title":"Asthma and corticosteroids: time for a more precise approach to treatment","volume":"49","author":"Dunican","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2022.06.050_bib41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1164\/ajrccm.156.1.9610113","article-title":"Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients","volume":"156","author":"Tan","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib42","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(75)90608-X","article-title":"Effect of intravenous prednisolone in asthmatics with diminished adrenergic responsiveness","volume":"2","author":"Ellul-Micallef","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.06.050_bib43","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib44","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S2213-2600(21)00124-7","article-title":"Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis","volume":"9","author":"Busse","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib45","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.rmed.2013.02.018","article-title":"Exhaled nitric oxide to predict corticosteroid responsiveness and reduce asthma exacerbation rates","volume":"107","author":"Donohue","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib46","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2022.06.050_bib47","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2022.06.050_bib48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/ACI.0000000000000704","article-title":"Fractional exhaled nitric oxide and asthma treatment adherence","volume":"21","author":"Butler","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.050_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100547","article-title":"Variability of type 2 inflammatory markers guiding biologic therapy of severe asthma: a 5-year retrospective study from a single tertiary hospital","volume":"14","author":"Li","year":"2021","journal-title":"World Allergy Organ J"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822007012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822007012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:36:11Z","timestamp":1761975371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822007012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2213219822007012"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.06.050","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma\u2014A Randomized, Placebo-Controlled Crossover Trial (MAPLE)","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.06.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}